CRBP Share Price | Corbus Pharmaceuticals Holdings, Inc. Stock Analysis & Recommendation

Q: How big is Corbus Pharmaceuticals Holdings, Inc.?

Market Cap: As of Jun 18, Corbus Pharmaceuticals Holdings, Inc. has a market capitalization of 101.32 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Corbus Pharmaceuticals reported net sales of 0.00 million and a net profit of -50.29 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 142.43 million, while total assets were reported at 155.88 million.

Q: What does Corbus Pharmaceuticals Holdings, Inc. do?

Overview:Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics for rare, chronic, and serious inflammatory and fibrotic diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.Financial Snapshot:Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025)Market cap: USD 101.32 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.03Return on Equity: -39.57%Price to Book: 0.80Contact Details:Address: 500 RIVER RIDGE DRIVE, NORWOOD MA : 02062Tel: ['1 617 9630103', '1 617 4157745']Website: https://www.corbuspharma.com/

Q: Is Corbus Pharmaceuticals Holdings, Inc. overvalued or undervalued?

As of 8 March 2022, the valuation grade for Corbus Pharmaceuticals Holdings, Inc. moved from risky to does not qualify, indicating a significant change in its perceived investment quality. The company is currently considered overvalued given its financial metrics. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at 0.89, and the EV to EBITDA is at 0.32, suggesting that the market may not be accurately pricing the company's potential.In comparison to its peers, Corbus Pharmaceuticals shows a stark contrast with ASP Isotopes, Inc. and ARCA biopharma, Inc., which have P/E ratios of -24.0140 and -5.3909, respectively. This places Corbus in a challenging position within its industry, where other companies are also struggling. The company's recent stock performance has been notably poor, with a year-to-date return of -33.14%, significantly underperforming the S&P 500's 2.44% return. Overall, the combination of these factors leads to the conclusion that Corbus Pharmaceuticals is overvalued in the current market environment.

Q: Is Corbus Pharmaceuticals Holdings, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Corbus Pharmaceuticals Holdings, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is bearish, indicating mixed signals. The RSI shows no signal on the weekly timeframe but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly. Daily moving averages are bullish, while the KST is bullish weekly but bearish monthly. Dow Theory indicates no trend weekly and mildly bullish monthly. OBV is mildly bullish across both weekly and monthly periods.In terms of multi-period returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 22.32% and 25.62% respectively, but it has significantly underperformed over the longer term, with a 1-year return of -76.44% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the bearish monthly indicators and significant long-term underperformance.

Results Declared: Corbus Pharmaceuticals Holdings, Inc. has declared results on 09 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

141.34 k

Shareholding (Dec 2025)

FII

9.98%

Held by 48 FIIs

DII

61.85%

Held by 20 DIIs

Promoter

10.16%

How big is Corbus Pharmaceuticals Holdings, Inc.?

22-Jun-2025

As of Jun 18, Corbus Pharmaceuticals Holdings, Inc. has a market capitalization of 101.32 million, with net sales of 0.00 million and a net profit of -50.29 million over the last four quarters. The company's shareholder's funds are 142.43 million, and total assets amount to 155.88 million.

View full answer

What does Corbus Pharmaceuticals Holdings, Inc. do?

22-Jun-2025

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for rare inflammatory and fibrotic diseases. It has a market cap of $101.32 million and reported a net profit loss of $17 million as of March 2025.

View full answer

Who are in the management team of Corbus Pharmaceuticals Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Corbus Pharmaceuticals Holdings, Inc. includes Mr. Alan Holmer (Independent Chairman), Mr. Yuval Cohen (CEO), and several Independent Directors: Mr. Avery Catlin, Ms. Rachelle Jacques, Dr. John Jenkins, and Dr. Peter Salzmann. They oversee the company's strategic direction and operations.

View full answer

Is Corbus Pharmaceuticals Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of March 8, 2022, Corbus Pharmaceuticals is considered overvalued due to its financial metrics, including a Price to Book Value of 0.89 and an EV to EBITDA of 0.32, while its stock has underperformed significantly with a year-to-date return of -33.14%.

View full answer

Is Corbus Pharmaceuticals Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Corbus Pharmaceuticals is in a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but significantly underperformed over the past year.

View full answer

Compare Corbus Pharmaceuticals Holdings, Inc. with Similar Stocks

ARCA biopharma, Inc.BeyondSpring, Inc.TherapeuticsMD, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 169 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.11

Return on Equity

-73.27%

Price to Book

1.83

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-21 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

6.17%

6 Months

-25.99%

1 Year

35.86%

2 Years

-79.34%

3 Years

38.71%

4 Years

-13.16%

5 Years

-86.73%

Corbus Pharmaceuticals Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

7.18%

EBIT to Interest (avg)

-51.96

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.83

EV to EBIT

-0.87

EV to EBITDA

-0.88

EV to Capital Employed

-6.37

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-73.27%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 25 Schemes (18.02%)

Foreign Institutions

Held by 48 Foreign Institutions (9.98%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 11.59% vs -31.64% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.90",
          "val2": "-24.30",
          "chgp": "9.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.60",
          "val2": "-23.30",
          "chgp": "11.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -95.27% vs 9.87% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-85.10",
          "val2": "-48.10",
          "chgp": "-76.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.90",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-78.50",
          "val2": "-40.20",
          "chgp": "-95.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-21.90

-24.30

9.88%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-20.60

-23.30

11.59%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 11.59% vs -31.64% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-85.10

-48.10

-76.92%

Interest

0.00

1.90

-100.00%

Exceptional Items

1.10

0.00

Consolidate Net Profit

-78.50

-40.20

-95.27%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -95.27% vs 9.87% in Dec 2024

All Annual Results

Company CV

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc.

Pharmaceuticals & Biotechnology

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Company Coordinates

Company Details

500 RIVER RIDGE DRIVE , NORWOOD MA : 02062

Tel: 1 617 96301031 617 4157745

https://www.corbuspharma.com/

Registrar Details